The divergent mitotic kinesin MKLP2 exhibits atypical structure and mechanochemistry

  1. Joseph Atherton
  2. I-Mei Yu
  3. Alexander Cook
  4. Joseph M Muretta
  5. Agnel Joseph
  6. Jennifer Major
  7. Yannick Sourigues
  8. Jeffrey Clause
  9. Maya Topf
  10. Steven S Rosenfeld
  11. Anne Houdusse
  12. Carolyn A Moores  Is a corresponding author
  1. Birkbeck College, United Kingdom
  2. Institut Curie, Centre National de la Recherche Scientifique, France
  3. University of Minnesota, United States
  4. Lerner Research Institute, Cleveland Clinic, United States

Abstract

MKLP2, a kinesin-6, has critical roles during the metaphase-anaphase transition and cytokinesis. Its motor domain contains conserved nucleotide binding motifs, but is divergent in sequence (~35% identity) and size (~40% larger) compared to other kinesins. Using cryo-electron microscopy and biophysical assays, we have undertaken a mechanochemical dissection of the microtubule-bound MKLP2 motor domain during its ATPase cycle, and show that many facets of its mechanism are distinct from other kinesins. While the MKLP2 neck-linker is directed towards the microtubule plus-end in an ATP-like state, it does not fully dock along the motor domain. Furthermore, the footprint of the MKLP2 motor domain on the MT surface is altered compared to motile kinesins, and enhanced by kinesin-6-specific sequences. The conformation of the highly extended loop6 insertion characteristic of kinesin-6s is nucleotide-independent and does not contact the MT surface. Our results emphasize the role of family-specific insertions in modulating kinesin motor function.

Data availability

The following data sets were generated

Article and author information

Author details

  1. Joseph Atherton

    Institute of Structural and Molecular Biology, Birkbeck College, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  2. I-Mei Yu

    Structural Motility, Institut Curie, Centre National de la Recherche Scientifique, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Alexander Cook

    Institute of Structural and Molecular Biology, Birkbeck College, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Joseph M Muretta

    Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Agnel Joseph

    Institute of Structural and Molecular Biology, Birkbeck College, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Jennifer Major

    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Clevelan, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Yannick Sourigues

    Structural Motility, Institut Curie, Centre National de la Recherche Scientifique, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Jeffrey Clause

    Structural Motility, Institut Curie, Centre National de la Recherche Scientifique, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Maya Topf

    Institute of Structural and Molecular Biology, Birkbeck College, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Steven S Rosenfeld

    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Anne Houdusse

    Structural Motility, Institut Curie, Centre National de la Recherche Scientifique, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  12. Carolyn A Moores

    Institute of Structural and Molecular Biology, Birkbeck College, London, United Kingdom
    For correspondence
    c.moores@mail.cryst.bbk.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5686-6290

Funding

Medical Research Council (MR/J000973/1)

  • Carolyn A Moores

Medical Research Council (MR/J003867/1)

  • Alexander Cook

Medical Research Council (MR/M019292/1)

  • Maya Topf

American Heart Association (SDG20480032)

  • Joseph M Muretta

National Institute of General Medical Sciences (GM102875 NS073610)

  • Steven S Rosenfeld

Centre National de la Recherche Scientifique

  • Anne Houdusse

Agence Nationale de la Recherche

  • Anne Houdusse

Ligue Contre le Cancer

  • Anne Houdusse

European Commission (Marie Curie Fellowship)

  • I-Mei Yu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2017, Atherton et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,885
    views
  • 648
    downloads
  • 41
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Joseph Atherton
  2. I-Mei Yu
  3. Alexander Cook
  4. Joseph M Muretta
  5. Agnel Joseph
  6. Jennifer Major
  7. Yannick Sourigues
  8. Jeffrey Clause
  9. Maya Topf
  10. Steven S Rosenfeld
  11. Anne Houdusse
  12. Carolyn A Moores
(2017)
The divergent mitotic kinesin MKLP2 exhibits atypical structure and mechanochemistry
eLife 6:e27793.
https://doi.org/10.7554/eLife.27793

Share this article

https://doi.org/10.7554/eLife.27793

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Angel D'Oliviera, Xuhang Dai ... Jeffrey S Mugridge
    Research Article

    The SARS-CoV-2 main protease (Mpro or Nsp5) is critical for production of viral proteins during infection and, like many viral proteases, also targets host proteins to subvert their cellular functions. Here, we show that the human tRNA methyltransferase TRMT1 is recognized and cleaved by SARS-CoV-2 Mpro. TRMT1 installs the N2,N2-dimethylguanosine (m2,2G) modification on mammalian tRNAs, which promotes cellular protein synthesis and redox homeostasis. We find that Mpro can cleave endogenous TRMT1 in human cell lysate, resulting in removal of the TRMT1 zinc finger domain. Evolutionary analysis shows the TRMT1 cleavage site is highly conserved in mammals, except in Muroidea, where TRMT1 is likely resistant to cleavage. TRMT1 proteolysis results in reduced tRNA binding and elimination of tRNA methyltransferase activity. We also determined the structure of an Mpro-TRMT1 peptide complex that shows how TRMT1 engages the Mpro active site in an uncommon substrate binding conformation. Finally, enzymology and molecular dynamics simulations indicate that kinetic discrimination occurs during a later step of Mpro-mediated proteolysis following substrate binding. Together, these data provide new insights into substrate recognition by SARS-CoV-2 Mpro that could help guide future antiviral therapeutic development and show how proteolysis of TRMT1 during SARS-CoV-2 infection impairs both TRMT1 tRNA binding and tRNA modification activity to disrupt host translation and potentially impact COVID-19 pathogenesis or phenotypes.

    1. Developmental Biology
    2. Structural Biology and Molecular Biophysics
    Elise S Bruguera, Jacob P Mahoney, William I Weis
    Research Article

    Wnt/β-catenin signaling directs animal development and tissue renewal in a tightly controlled, cell- and tissue-specific manner. In the mammalian central nervous system, the atypical ligand Norrin controls angiogenesis and maintenance of the blood-brain barrier and blood-retina barrier through the Wnt/β-catenin pathway. Like Wnt, Norrin activates signaling by binding and heterodimerizing the receptors Frizzled (Fzd) and low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6), leading to membrane recruitment of the intracellular transducer Dishevelled (Dvl) and ultimately stabilizing the transcriptional coactivator β-catenin. Unlike Wnt, the cystine knot ligand Norrin only signals through Fzd4 and additionally requires the co-receptor Tetraspanin12 (Tspan12); however, the mechanism underlying Tspan12-mediated signal enhancement is unclear. It has been proposed that Tspan12 integrates into the Norrin-Fzd4 complex to enhance Norrin-Fzd4 affinity or otherwise allosterically modulate Fzd4 signaling. Here, we measure direct, high-affinity binding between purified Norrin and Tspan12 in a lipid environment and use AlphaFold models to interrogate this interaction interface. We find that Tspan12 and Fzd4 can simultaneously bind Norrin and that a pre-formed Tspan12/Fzd4 heterodimer, as well as cells co-expressing Tspan12 and Fzd4, more efficiently capture low concentrations of Norrin than Fzd4 alone. We also show that Tspan12 competes with both heparan sulfate proteoglycans and LRP6 for Norrin binding and that Tspan12 does not impact Fzd4-Dvl affinity in the presence or absence of Norrin. Our findings suggest that Tspan12 does not allosterically enhance Fzd4 binding to Norrin or Dvl, but instead functions to directly capture Norrin upstream of signaling.